Transition Therapeutics Inc. (Nasdaq: TTHI) 39.5% HIGHER; announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms (NPS) in Alzheimer’s disease (AD). The FDA concluded that the development program for ELND005 for the treatment of NPS in AD meets their criteria for Fast Track Designation.
Jakks Pacific, Inc. (NASDAQ: JAKK) 19.3% LOWER; reported Q2 EPS of ($2.14), $2.19 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $106.2 million versus the consensus estimate of $147.74 million. Sees FY2013 EPS of $-2.56, versus prior guidance of $0.63-$0.68 and the consensus of $0.45. Jakks Pacific, Inc. sees FY2013 revenue of $620 million, versus prior guidance of $694-$700 million and the consensus of $693.8 million.
Gilat Satellite Networks Ltd. (Nasdaq: GILT) 12.9% LOWER; revised its management objective targets for 2013. Revenue for 2013 is now expected to be between $335 million to $345 million as compared to the previously stated range of $350 million to $360 million and EBITDA is expected to be approximately 7% as compared to 9%. *** The Street sees FY13 revs of $354.9 million.
Inovio Pharmaceuticals, Inc. (NYSE: INO) 12.5% HIGHER; announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia (CLI) and other forms of peripheral arterial disease (PAD). CLI’s severe blockage of arteries of the lower extremities markedly reduces blood flow, resulting in notable medical impacts and death. In a mouse model, delivery of a synthetically optimized hypoxia-inducible factor-1 alpha (HIF-1) gene using Inovio’s CELLECTRA® electroporation delivery technology produced significant growth of new blood vessels and improved limb blood flow, limb function recovery, and survival from limb necrosis and amputation. The results were published in a paper entitled, “In vivo electroporation of constitutively expressed HIF-1 plasmid DNA improves neovascularization in a mouse model of limb ischemia,” in the peer-reviewed Journal of Vascular Surgery.
Sherwin-Williams Co. (NYSE: SHW) 10% LOWER; reported Q2 EPS of $2.54, $0.02 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $2.7 billion versus the consensus estimate of $2.78 billion. Sherwin-Williams Co. sees Q3 2013 EPS of $2.55-2.65, versus the consensus of $2.80. Net sales will increase six to nine percent compared to last year’s third quarter. Sherwin-Williams Co. sees FY2013 EPS of $7.45-7.55, versus the consensus of $8.08. For the full year 2013, they expect consolidated net sales to increase above 2012 levels by a mid single digit percentage.
Cypress Semiconductor (NASDAQ: CY) 9.7% HIGHER; reported Q2 EPS of $0.14, $0.07 better than the analyst estimate of $0.07. Revenue for the quarter came in at $193.47 million versus the consensus estimate of $182.79 million.
Select Comfort Corp (NASDAQ: SCSS) 7.5% LOWER; reported Q2 EPS of $0.18, $0.06 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $207.4 million versus the consensus estimate of $210.76 million. The company is maintaining its outlook for full-year 2013 GAAP earnings per diluted share of between $1.30 and $1.45.
Glu Mobile (NASDAQ: GLUU) 7.3% HIGHER; Glu Mobile Inc. and MGM Interactive Inc. entered into a warrant initially exercisable to purchase up to 3,333,333 shares of the Company’s common stock at an initial exercise price of $3.00 per share, subject to adjustments for dividends, reorganizations and other common stock events. The Warrant expires on July 15, 2018.
eBay Inc. (NASDAQ: EBAY) 6.2% HIGHER; reported Q2 EPS of $0.63, $0.01 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.89 billion. eBay, Inc. sees Q3 2013 EPS of $0.61-0.63, versus the consensus of $0.65. eBay, Inc. sees Q3 2013 revenue of $3.85-3.95 billion, versus the consensus of $3.97 billion. eBay, Inc. sees FY2013 EPS of $2.70-2.75, versus the consensus of $2.75. eBay, Inc. sees FY2013 revenue of $16-16.5 billion, versus the consensus of $16.31 billion.
Johnson Controls, Inc. (NYSE: JCI) 5.7% HIGHER; reported Q3 EPS of $0.78, $0.03 better than the analyst estimate of $0.75. Revenue for the quarter came in at $10.83 billion versus the consensus estimate of $10.97 billion. Sees Q4 2013 EPS of $0.93-$0.95, versus the consensus of $0.92. Sees FY2013 EPS of $2.64-$2.66, versus the consensus of $2.61
Plexus Corp (NASDAQ: PLXS) 5.3% HIGHER; reported Q3 EPS of $0.68, $0.10 better than the analyst estimate of $0.58. Revenue for the quarter came in at $571.95 million versus the consensus estimate of $564.99 million. Plexus Corp sees Q4 2013 EPS of $0.60-0.66, versus the consensus of $0.57. Plexus Corp sees Q4 2013 revenue of $545-575 million, versus the consensus of $564.99 million.
Organovo (AMEX: ONVO) 4.2% LOWER; filed a registration with the U.S. SEC to sell, from time to time, up to $100 million of Common Stock, Preferred Stock, Debt Securities, Warrants, Units, or any combination thereof.
Intel (NASDAQ: INTC) 4.1% LOWER; reported Q2 EPS of $0.39, in-line with the analyst estimate of $0.39. Revenue for the quarter came in at $12.8 billion versus the consensus estimate of $12.89 billion. Intel sees Q313 revenue of $13.5 million, +/- $500 million. Sees gross margins at 61 percent +/- a few percentage points. Sees FY13 revs approximately flat year-on-year, down from prior expectations of low single digit percentage increase. Sees gross margin around 59 percent, down from 60 percent +/- a few percentage points.
Morgan Stanley (NYSE: MS) 4% HIGHER; reported Q2 EPS of $0.37, $0.07 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $8.3 billion versus the consensus estimate of $7.93 billion. Net income and revs in the same period last year, ex-DVA, were $0.16 and $6.6 billion.
Sallie Mae (NASDAQ: SLM) 4% HIGHER; reported Q2 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. The company also authorized a $400 million stock buyback
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) 3.5% HIGHER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the proposed offering are to be sold by AcelRx.
TG Therapeutics, Inc. (Nasdaq: TGTX) 3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Xilinx, Inc. (NASDAQ: XLNX) 2.9% HIGHER; reported Q1 EPS of $0.56, $0.09 better than the analyst estimate of $0.47. Revenue for the quarter came in at $579 million versus the consensus estimate of $549.32 million. Sees Q214 sales flat to up 3% sequentially.
IBM (NYSE: IBM) 2.5% HIGHER; reported Q2 EPS of $3.91, $0.14 better than the analyst estimate of $3.77. Revenue for the quarter came fell 3% to $24.9 billion versus the consensus estimate of $25.39 billion. Sees FY EPS expectation of at least $16.90, versus the consensus of $16.64.
Sandisk Corp (NASDAQ: SNDK) 2.2% HIGHER; reported Q2 EPS of $1.21, $0.29 better than the analyst estimate of $0.92. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.48 billion.
Micron (NYSE: MU) 2% HIGHER; Up on SanDisk results
Dell (NASDAQ: DELL) 1.6% HIGHER; Dell shareholder meeting adjourned as Michael Dell may note have enough vote. This has increased speculation of a higher bid.
Marriott Vacations Worldwide (NYSE: VAC) 1.5% HIGHER; reported Q2 EPS of $0.73, $0.26 better than the analyst estimate of $0.47. Revenue for the quarter came in at $421 million versus the consensus estimate of $403.25 million. Marriott Vacations Worldwide sees FY2013 EPS of $1.94-2.10, versus prior guidance of $1.87-2.03. The consensus is $2.02.
American Express Co. (NYSE: AXP) 1.3% LOWER; reported Q2 EPS of $1.27, $0.06 better than the analyst estimate of $1.21. Revenue for the quarter came in at $8.25 billion versus the consensus estimate of $8.32 billion.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW
*NEW – Download StreetInsider’s FREE iPhone and iPad App –